Send to

Choose Destination
Ear Nose Throat J. 2013 Aug;92(8):364-71.

A systematic review of proton-pump inhibitor therapy for laryngopharyngeal reflux.

Author information

Department of Otolaryngology, Queens Hospital Center, 82-68 164th St., Jamaica, NY 11432, USA.


The author performed a MEDLINE literature search to identify and evaluate all randomized, placebo-controlled trials of the treatment of laryngopharyngeal reflux (LPR) with an oral proton-pump inhibitor (PPI) that have been published since 1966. Eight such trials that included a total of 358 patients were identified. These eight studies contained seven different definitions of LPR. Validity scores (maximum: 9) ranged from 5 to 9 (mean: 7.5). One study investigated low-dose once-daily therapy, two studies investigated low-dose twice-daily therapy, and five studies investigated high-dose twice-daily therapy. Outcomes measures were not consistent among studies, and most studies used unvalidated outcomes measures. Only two studies found that a PPI was significantly better than placebo-one in the low-dose twice-daily group and one in the high-dose twice-daily group. The author concludes that the current body of literature is insufficient to draw reliable conclusions about the efficacy of PPI therapy for the treatment of LPR.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center